Announcements

Conference: 29th Congress of the European Association for Cancer Research
Date: 12–15 June 2023
Place: Torino, Italy

MDPI will be attending the 29th Congress of the European Association for Cancer Research, held in Torino, Italy, from 12 to 15 June 2023. This conference aims to achieve an in-depth exchange of the latest research results in the field of basic research, clinical application, cutting-edge technology, and industrial development in the field of cancer research over the year. During this conference, MDPI will welcome researchers from different backgrounds to visit and share their latest ideas with us.

The following MDPI journals will be represented:

• Cells;
• Cancers;
• Children;
• CIMB;
• Current Oncology;
• Diagnostics;
• Geriatrics;
• Healthcare;
• JCM;
• Medical Sciences.

If you are attending this conference, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://www.eacr2023.org/.

Conference: The 112th Annual Meeting of the Japanese Society of Pathology
Date: 13–15 April 2023
Place: Shimonoseki, Japan

MDPI will be attending the 112th Annual Meeting of the Japanese Society of Pathology as an exhibitor. This meeting will be held in Shimonoseki, Japan, from 13 to 15 April 2023. This conference is held every year, and the theme of the 112th edition is “Doors to Overcoming Intractable Diseases: Potential of Pathology and Pathological Diagnostics”. The aim of this meeting is to provide an opportunity for all the members who chose the path of pathology to engage in hot discussions and introduce new perspectives to pathology and diagnostic pathology.

The following MDPI journals will be represented:

• Cancers;
• Diagnostics;
• JPM;
• Pathogens;
• CIMB;
• Pathophysiology.

If you are attending this conference, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://site2.convention.co.jp/112jsp/english/.

We are delighted to announce one of the winners of the Cancers 2022 Best Ph.D. Thesis Award— Dr. Adria Cañellas Socias, from the University of Barcelona, Spain, for his thesis entitled “Metastatic Recurrence in Colorectal Cancer Arises from Residual EMP1+ Cells”.

We have received a large number of excellent essays from Ph.D. students and postdocs. We would like to thank the award committee for their excellent work in the hard task of selecting winners from such excellent candidates, as well as everyone who participated in this award and helped make it a huge success!

The winners will receive CHF 800, a certificate, and a chance to publish a paper free of charge after peer review in Cancers (ISSN: 2072-6694) before the end of 2023.

We are delighted to announce one of the winners of the Cancers 2022 Best Ph.D. Thesis Award—Dr. João Pedro da Silva Machado Lobo, from the University of Porto, Portugal, for his thesis entitled “Uncovering Novel Prognostic and Predictive Epigenetic Biomarkers in Malignant Testicular Germ Cell Tumors”.

We have received a large number of excellent essays from Ph.D. students and postdocs. We would like to thank the award committee for their excellent work in the hard task of selecting winners from such excellent candidates, as well as everyone who participated in this award and helped make it a huge success!

The winners will receive CHF 800, a certificate, and a chance to publish a paper free of charge after peer review in Cancers (ISSN: 2072-6694) before the end of 2023.

MDPI will be attending the Chinese Academic Conference on Tumor Biomarker, held in Shanghai, China, from 7 to 9 April 2023. This conference aims to achieve an in-depth exchange of the latest research results in the field of basic research, clinical application, cutting-edge technology, and industrial development in the field of tumor markers over the year. During this conference, MDPI will welcome researchers from different backgrounds to visit and share their latest inspirations with us.

The following MDPI journals will be represented:

• Biomedicines;
• Cancers;
• Cells;
• Diagnostics;
• Current Oncology;
• JPM;
• JCM;
• Onco;
• CIMB;
• BioMedInformatics.

If you plan on attending this conference, feel free to stop by our booth, #B155. Our delegates look forward to meeting you in person to answer any questions you may have.

For more information about the conference, please follow the link below: https://biomarker2022.sciconf.cn/cn/web/index/13496.

We are delighted to announce the winners of the Cancers 2022 Young Investigator Award. Additionally, we want to thank the award committee for their excellent work in the hard task of selecting a winner from such excellent candidates, as well as everyone who participated in this award and helped ensure it was a huge success!

A special congratulations to the winners—Dr. Ashleigh Poh and Dr. Miranda Fidler-Benaoudia.

Dr. Ashleigh Poh is an early career post-doctoral research fellow at the Olivia Newton-John Cancer Research Institute, Australia. She received her Ph.D. in 2017. Her work focuses on therapeutic approaches to re-invigorate anti-tumor immunity by reprogramming immunosuppressive myeloid cells towards an immune-stimulatory endotype. Dr. Ashleigh Poh’s research was the first to identify a tumor cell-extrinsic role for the myeloid-specific kinase HCK in solid cancers by enhancing the polarization of immunosuppressive ‘alternatively activated’ macrophages. These discoveries have leveraged major industry partnerships to develop small molecule HCK inhibitors for clinical use. Dr. Ashleigh Poh independently secured more than 1.5 million dollars in competitive funding as a principal investigator. Her ability to generate high-quality research is also evidenced by her winning 20 awards and delivering 30 invited presentations. Dr. Ashleigh Poh’s expertise in tumor immunology has resulted in 23 publications (13 as first/senior author) in prestigious journals including Cell, Cancer Cell and Science Advances.

Dr. Miranda Fidler-Benaoudia is a cancer epidemiologist/research scientist at Alberta Health Services, Canada, and is an Adjunct Assistant Professor at the University of Calgary, Canada. Her research focuses on understanding the magnitude of the late effects among survivors of childhood, adolescent and young adult cancer and developing tertiary prevention interventions to mitigate cancer- and treatment-related sequalae. She is interested in sub-populations, such as indigenous peoples, and she comprehensively undertakes research to describe cancer indicators nationally, regionally and globally. Prior to her current positions, she received her Ph.D. at the University of Birmingham, UK, in 2015, and completed a postdoctoral fellowship at the International Agency for Research on Cancer, France, from 2015 to 2018. She has significantly contributed to the field of oncology as a young investigator, with 44 peer-reviewed publications, 4 invited oral presentations and 34 oral/poster presentations, as well as numerous memberships on editorial boards and national committees. Finally, she has received over 2.1 million dollars in funding as the nominated principal applicant since commencing her independent research four years ago.

Please join us in congratulating Dr. Ashleigh Poh and Dr. Miranda Fidler-Benaoudia for their outstanding achievements.

As the awardees, they will receive an honorarium of CHF 2000, an electronic certificate, an offer to publish a paper free of charge before the end of 2023 in Cancers (ISSN: 2072-6694) after peer review and an engraved plaque.

We thank all those who nominated a candidate from various fields of study for their participation and all the Award Committee members for their evaluation of the many excellent nominees.

1. “The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis”
   by Deniz Can Guven, Taha Koray Sahin, Enes Erul, Saadettin Kilickap, Thilo Gambichler and Sercan Aksoy
   Cancers 2022, 14(11), 2675; https://doi.org/10.3390/cancers14112675
   Available online: https://www.mdpi.com/2072-6694/14/11/2675

2. “Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy”
   by Yuta Myojin, Takahiro Kodama, Ryotaro Sakamori, Kazuki Maesaka, Takayuki Matsumae, Yoshiyuki Sawai, Yasuharu Imai, Kazuyoshi Ohkawa, Masanori Miyazaki, Satoshi Tanaka et al.
   Cancers 2022, 14(4), 883; https://doi.org/10.3390/cancers14040883
   Available online: https://www.mdpi.com/2072-6694/14/4/883

3. “HPRT1 Promotes Chemoresistance in Oral Squamous Cell Carcinoma via Activating MMP1/PI3K/Akt Signaling Pathway”
   by Tong Wu, Zan Jiao, Yixuan Li, Xuan Su, Fan Yao, Jin Peng, Weichao Chen and Ankui Yang
   Cancers 2022, 14(4), 855; https://doi.org/10.3390/cancers14040855
   Available online: https://www.mdpi.com/2072-6694/14/4/855

4. “Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy”
   by Pauline Gilson, Jean-Louis Merlin and Alexandre Harlé
   Cancers 2022, 14(6), 1384; https://doi.org/10.3390/cancers14061384
   Available online: https://www.mdpi.com/2072-6694/14/6/1384

5. “Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer”
   by Camille Domergue, Elodie Martin, Camille Lemarié, Pascal Jézéquel, Jean-Sebastien Frenel, Paule Augereau, Mario Campone and Anne Patsouris
   Cancers 2022, 14(10), 2509; https://doi.org/10.3390/cancers14102509
   Available online: https://www.mdpi.com/2072-6694/14/10/2509

6. “Comprehensive Approach to Distinguish Patients with Solid Tumors from Healthy Controls by Combining Androgen Receptor Mutation p.H875Y with Cell-Free DNA Methylation and Circulating miRNAs”
   by Elena Tomeva, Olivier J. Switzeny, Clemens Heitzinger, Berit Hippe and Alexander G. Haslberger
   Cancers 2022, 14(2), 462; https://doi.org/10.3390/cancers14020462
   Available online: https://www.mdpi.com/2072-6694/14/2/462

7. “Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma”
   by Mariella Faccia, Matteo Garcovich, Maria Elena Ainora, Laura Riccardi, Maurizio Pompili, Antonio Gasbarrini and Maria Assunta Zocco
   Cancers 2022, 14(3), 481; https://doi.org/10.3390/cancers14030481
   Available online: https://www.mdpi.com/2072-6694/14/3/481

8. “Long Noncoding RNA LINC02470 Sponges MicroRNA-143-3p and Enhances SMAD3-Mediated Epithelial-to-Mesenchymal Transition to Promote the Aggressive Properties of Bladder Cancer”
   by Cheng-Shuo Huang, Chen-Hua Tsai, Cheng-Ping Yu, Ying-Si Wu, Ming-Fong Yee, Jar-Yi Ho and Dah-Shyong Yu
   Cancers 2022, 14(4), 968; https://doi.org/10.3390/cancers14040968
   Available online: https://www.mdpi.com/2072-6694/14/4/968

9. “Imaging Kv1.3 Expressing Memory T Cells as a Marker of Immunotherapy Response”
   by Julian L. Goggi, Shivashankar Khanapur, Boominathan Ramasamy, Siddesh V. Hartimath, Tang Jun Rong, Peter Cheng, Yun Xuan Tan, Xin Yi Yeo, Sangyong Jung, Stephanie Shee Min Goay et al.
   Cancers 2022, 14(5), 1217; https://doi.org/10.3390/cancers14051217
   Available online: https://www.mdpi.com/2072-6694/14/5/1217

10. “Automatically Extracted Machine Learning Features from Preoperative CT to Early Predict Microvascular Invasion in HCC: The Role of the Zone of Transition (ZOT)”
    by Matteo Renzulli, Margherita Mottola, Francesca Coppola, Maria Adriana Cocozza, Silvia Malavasi, Arrigo Cattabriga, Giulio Vara, Matteo Ravaioli, Matteo Cescon, Francesco Vasuri et al.
    Cancers 2022, 14(7), 1816; https://doi.org/10.3390/cancers14071816
    Available online: https://www.mdpi.com/2072-6694/14/7/1816

1. “Environmental Risk Factors for Childhood Acute Lymphoblastic Leukemia: An Umbrella Review”
   by Felix M. Onyije, Ann Olsson, Dan Baaken, Friederike Erdmann, Martin Stanulla, Daniel Wollschläger and Joachim Schüz
   Cancers 2022, 14(2), 382; https://doi.org/10.3390/cancers14020382
   Available online: https://www.mdpi.com/2072-6694/14/2/382

2. “Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth”
   by Rameswari Chilamakuri and Saurabh Agarwal
   Cancers 2022, 14(4), 1067; https://doi.org/10.3390/cancers14041067
   Available online: https://www.mdpi.com/2072-6694/14/4/1067

3. “Gastrointestinal Adenocarcinoma Incidence and Survival Trends in South Australia, 1990–2017”
   by Dominique Schell, Shahid Ullah, Mark E. Brooke-Smith, Paul Hollington, Marina Yeow, Christos S. Karapetis, David I. Watson, Stephen J. Pandol, Claire T. Roberts and Savio G. Barreto
   Cancers 2022, 14(2), 275; https://doi.org/10.3390/cancers14020275
   Available online: https://www.mdpi.com/2072-6694/14/2/275

4. “Management of Nutritional Needs in Pediatric Oncology: A Consensus Statement”
   by Francesco Fabozzi, Chiara Maria Trovato, Antonella Diamanti, Angela Mastronuzzi, Marco Zecca, Serena Ilaria Tripodi, Riccardo Masetti, Davide Leardini, Edoardo Muratore, Veronica Barat et al.
   Cancers 2022, 14(14), 3378; https://doi.org/10.3390/cancers14143378
   Available online: https://www.mdpi.com/2072-6694/14/14/3378

5. “NanoString Digital Molecular Profiling of Protein and microRNA in Rhabdomyosarcoma”
   by Atif A. Ahmed, Midhat S. Farooqi, Sultan S. Habeebu, Elizabeth Gonzalez, Terrie G. Flatt, Ashley L. Wilson and Frederic G. Barr
   Cancers 2022, 14(3), 522; https://doi.org/10.3390/cancers14030522
   Available online: https://www.mdpi.com/2072-6694/14/3/522

6. “Cannabinol Inhibits Cellular Proliferation, Invasion, and Angiogenesis of Neuroblastoma via Novel miR-34a/tRiMetF31/PFKFB3 Axis”
   by Bo Wang, Dongping Li, Viktoriia Cherkasova, Marta Gerasymchuk, Aru Narendran, Igor Kovalchuk and Olga Kovalchuk
   Cancers 2022, 14(8), 1908; https://doi.org/10.3390/cancers14081908
   Available online: https://www.mdpi.com/2072-6694/14/8/1908

7. “New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma”
   by Francia Y. Fang, Jared S. Rosenblum, Winson S. Ho and John D. Heiss
   Cancers 2022, 14(9), 2285; https://doi.org/10.3390/cancers14092285
   Available online: https://www.mdpi.com/2072-6694/14/9/2285

8. “Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins”
   by Charlie Buchou, Karine Laud-Duval, Wietske van der Ent, Sandrine Grossetête, Sakina Zaidi, Géraldine Gentric, Maxime Corbé, Kévin Müller, Elaine Del Nery, Didier Surdez et al.
   Cancers 2022, 14(9), 2327; https://doi.org/10.3390/cancers14092327
   Available online: https://www.mdpi.com/2072-6694/14/9/2327

9. “Computer-Based Cognitive Training in Children with Primary Brain Tumours: A Systematic Review”
   by Francesco Sciancalepore, Leonardo Tariciotti, Giulia Remoli, Danilo Menegatti, Andrea Carai, Giuseppe Petruzzellis, Kiersten P. Miller, Francesco Delli Priscoli, Alessandro Giuseppi, Roberto Premuselli et al.
   Cancers 2022, 14(16), 3879; https://doi.org/10.3390/cancers14163879
   Available online: https://www.mdpi.com/2072-6694/14/16/3879

10. “Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol”
    by Ewa Koscielniak, Bernd Blank, Christian Vokuhl, Bernarda Kazanowska, Ruth Ladenstein, Felix Niggli, Gustaf Ljungman, Rupert Handgretinger, Guido Seitz, Jörg Fuchs et al.
    Cancers 2022, 14(4), 899; https://doi.org/10.3390/cancers14040899
    Available online: https://www.mdpi.com/2072-6694/14/4/899

As a leading open access publisher, MDPI provides scholars with a high-quality and rich academic exchange platform by continuously expanding into new and exciting research areas.

In December 2022, MDPI launched five new journals, covering multiple subjects such as life sciences, biology, medicine and pharmacology, social sciences and humanities. These new journals are being edited by established scholars across the world.

If you are interested in creating more open access journals with us to publish cutting-edge research, please send your journal proposal application to newjournal-committee@mdpi.com.

1. “Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets”
by Ralf-Peter Czekay, Dong-Joo Cheon, Rohan Samarakoon, Stacie M. Kutz and Paul J. Higgins
Cancers 2022, 14(5), 1231; https://doi.org/10.3390/cancers14051231
Available online: https://www.mdpi.com/2072-6694/14/5/1231

2. “AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis”
by Marie-Anne Goyette and Jean-François Côté
Cancers 2022, 14(3), 466; https://doi.org/10.3390/cancers14030466
Available online: https://www.mdpi.com/2072-6694/14/3/466

3. “Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy”
by Leah Davis, Matthias Recktenwald, Evan Hutt, Schuyler Fuller, Madison Briggs, Arnav Goel and Nichole Daringer
Cancers 2022, 14(5), 1259; https://doi.org/10.3390/cancers14051259
Available online: https://www.mdpi.com/2072-6694/14/5/1259

4. “Cytokine-Induced Senescence in the Tumor Microenvironment and Its Effects on Anti-Tumor Immune Responses”
by Maximilian Rentschler, Heidi Braumüller, Priscilla S. Briquez and Thomas Wieder
Cancers 2022, 14(6), 1364; https://doi.org/10.3390/cancers14061364
Available online: https://www.mdpi.com/2072-6694/14/6/1364

5. “Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context”
by Mannon Geindreau, Mélanie Bruchard and Frédérique Vegran
Cancers 2022, 14(10), 2446; https://doi.org/10.3390/cancers14102446
Available online: https://www.mdpi.com/2072-6694/14/10/2446

6. “STAT3 Signaling in Breast Cancer: Multicellular Actions and Therapeutic Potential”
by Sarah Q. To, Rhynelle S. Dmello, Anna K. Richards, Matthias Ernst and Ashwini L. Chand
Cancers 2022, 14(2), 429; https://doi.org/10.3390/cancers14020429
Available online: https://www.mdpi.com/2072-6694/14/2/429

7.“Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy”
by Jang Hyun Park and Heung Kyu Lee
Cancers 2022, 14(5), 1176; https://doi.org/10.3390/cancers14051176
Available online: https://www.mdpi.com/2072-6694/14/5/1176

8. “Impact of Lipid Metabolism on Antitumor Immune Response”
by Nesrine Mabrouk, Baptiste Lecoeur, Ali Bettaieb, Catherine Paul and Frédérique Végran
Cancers 2022, 14(7), 1850; https://doi.org/10.3390/cancers14071850
Available online: https://www.mdpi.com/2072-6694/14/7/1850

9. “Therapeutic Potential of Naturally Occurring Small Molecules to Target the Wnt/β-Catenin Signaling Pathway in Colorectal Cancer”
by Luiz F. S. Oliveira, Danilo Predes, Helena L. Borges and Jose G. Abreu
Cancers 2022, 14(2), 403; https://doi.org/10.3390/cancers14020403
Available online: https://www.mdpi.com/2072-6694/14/2/403

10. “Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment”
by Nan Sethakorn, Erika Heninger, Cristina Sánchez-de-Diego, Adeline B. Ding, Ravi Chandra Yada, Sheena C. Kerr, David Kosoff, David J. Beebe and Joshua M. Lang
Cancers 2022, 14(3), 757; https://doi.org/10.3390/cancers14030757
Available online: https://www.mdpi.com/2072-6694/14/3/757